AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference

On September 11, 2020 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, reported that it will showcase recent progress in its clinical programs targeting Tau for neurodegenerative diseases at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference (Press release, AC Immune, SEP 11, 2020, View Source [SID1234565023]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AC Immune CEO Prof. Andrea Pfeifer, Ph.D., will discuss the Company’s comprehensive anti-Tau clinical pipeline, which leads the industry in addressing this important neurodegenerative pathology. The extent of Tau pathology correlates very strongly with clinical decline throughout the course of disease, and AC Immune’s three clinical-stage therapeutic assets – an antibody, a small molecule inhibitor, and a vaccine – collectively target the full spectrum of Tau pathology by inhibiting both early intracellular Tau aggregation and extracellular seeding and spreading of pathological Tau protein. Prof. Pfeifer will also discuss recently published results demonstrating the ability of its differentiated Tau positron emission tomography (PET) imaging agent PI-2620, which was discovered in a research collaboration with Life Molecular Imaging, to potentially facilitate an earlier and more reliable diagnosis of patients with progressive supranuclear palsy (PSP).

H.C. Wainwright 22nd Annual Global Investment Conference
Date: September 15, 2020 | 10:00–10:20 am ET / 4:00–4:20 pm CET
Format: Virtual Presentation followed by Q&A
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA

The presentation will be followed by a question and answer session. A webcast of the presentation and Q&A will be available on the Events Page of AC Immune’s website.